论文部分内容阅读
目前中国医药的1/2以上是老年人消费的,而现在中国老龄人口已超2亿,2010-2030年老龄化加速,到2020年老龄人口将达到2.5亿,到2050年老龄人口将达到顶峰4亿。中国人口老龄化的趋势对生物医药行业来说既是机遇又是挑战,行业中各领域的未来发展都必须考虑到这一重要影响因素。因此在下一步的“十三五”战略性新兴产业规划中,建议全面而有步骤地发展健康老龄化的产业,以“医老”产业为主体,促进社会经济建设。
At present, more than one-half of Chinese medicine is consumed by the elderly. Now that the population of China has exceeded 200 million, the aging of population in 2010-2030 is accelerating. By 2020, the number of the aged will reach 250 million. By 2050, the aged population will reach its peak 400000000. The trend of population aging in China is both an opportunity and a challenge for the biopharmaceutical industry. The future development of various fields in the industry must take this important influencing factor into account. Therefore, in the next strategic planning of “13th Five-Year Plan”, it is suggested that a healthy and aging industry be developed in an all-round and step-by-step manner, with “old-age” industries as the mainstay to promote social and economic development.